Claritus Pharmaceuticals Inc. (CLAZF)

[TheShadow]

The AccDist indicator has been in positive territory for KALTF since 07/17/18.
KALY dropped this PR on 07/19/18.

Kalytera Therapeutics Inc (TSX-V: KALY, OTCQB: KALTF) is moving into the medical cannabis market.

The cannabinoid, or CBD, therapeutics developer is acquiring all rights to Beetlebung Pharma Ltd’s medical cannabis products for the treatment of both dermatologic diseases and women’s health.

The agreement gives Kalytera the option to license certain formulas from Beetlebung and bring them to markets where cannabis has been approved for medical use, allowing the biopharma to take a shortcut past the FDA approval process straight to revenues. Kalytera paid the Israel-based company an initial fee of US$25,000 to secure the option. If the option is exercised, an additional US$25,000 plus patent costs and other fees will be paid to Beetlebung.

Two of the products licensed include topical medical cannabis extracts that can be used to treat psoriasis and dysmenorrhea, or severe menstrual cramps.

Kalytera develops CBD therapeutics to treat acute and chronic pain.

http://www.proactiveinvestors.com/companies/news/201176/kalytera-therapeutics-enters-medical-cannabis-market-acquiring-rights-to-womens-health-treatments-201176.html

https://www.otcmarkets.com/stock/KALTF/news/Kalytera-to-Enter-Medical-Cannabis-Market-With-Focus-on-Treatment-of-Psoriasis-and-Menstrual-Cramps?id=198422